Skip to main content

Eli Lilly vs Novo Nordisk: Revenue, Profit and Business Model

Eli Lilly had $65.2B of annual revenue in FY2025 and $20.6B of net income. Novo Nordisk had ~$47B of annual revenue in FY2025 and ~$15.6B of net income.

Latest financial snapshot

Eli Lilly

Latest annual revenue
$65.2B (FY2025)
Net income
$20.6B
Net margin
31.7%
Revenue growth
+13.3% a year, FY2016–FY2025

Novo Nordisk

Latest annual revenue
~$47B (FY2025)
Net income
~$15.6B
Net margin
33.1%
Revenue growth
+16.8% a year, FY2019–FY2025

Financial summary

Eli Lilly

Revenue rose from $28.5 billion in 2022 to $45.0 billion in 2024 and $65.2 billion in 2025, while net income nearly doubled to $20.6 billion. Growth accelerated again in 2026: second-quarter revenue rose 48% to $23.0 billion, with Mounjaro at $9.94 billion (up 91%) and Zepbound at $4.93 billion. Lilly raised 2026 revenue guidance to $85-87 billion and non-GAAP EPS guidance to $35.50-36.50. Capital expenditures reached $7.8 billion in 2025 as Lilly expanded production capacity. Eli Lilly and Company is a pharmaceutical titan that has experienced massive growth, commanding a monumental market valuation frequently exceeding $700 billion.

Novo Nordisk

Sales grew from ~$18.5B (DKK 122.0B) in 2019 to ~$47B (DKK 309.1B) in 2025, and net profit rose from ~$5.93B (DKK 39.0B) to ~$15.6B (DKK 102.4B), driven by Ozempic and Wegovy. Growth slowed to 6.4% in reported DKK in 2025 as US prices fell and competition rose. In H1 2026 reported sales were ~$26.6B (DKK 175.3B), inflated by a one-off 340B rebate provision reversal; adjusted sales were ~$22.6B (DKK 148.6B). Q2 2026 adjusted sales rose 7% at constant exchange rates, and management guided full-year 2026 adjusted sales and operating profit growth of 0% to -6% at CER.

Revenue and profit by year

Eli Lilly

Eli Lilly revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$65.2B$20.6B31.7%+44.7%Source
FY2024$45B$10.6B23.5%+32.0%Source
FY2023$34.1B$5.2B15.4%+19.6%Source
FY2022$28.5B$6.2B21.9%+0.8%Source
FY2021$28.3B$5.6B19.7%+15.4%Source
FY2020$24.5B$6.2B25.2%+9.9%Source
FY2019$22.3B$8.3B37.3%+3.8%Source
FY2018$21.5B$3.2B15.0%+7.6%Source
FY2017$20B-$204.1M-1.0%-5.9%Source
FY2016$21.2B———Source
Full Eli Lilly financials

Novo Nordisk

Novo Nordisk revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025~$47B~$15.6B33.1%+6.4%Source
FY2024~$44.1B~$15.4B34.8%+25.0%Source
FY2023~$35.3B~$12.7B36.0%+31.3%Source
FY2022~$26.9B~$8.4B31.4%+25.7%Source
FY2021~$21.4B~$7.3B33.9%+10.9%Source
FY2020~$19.3B~$6.4B33.2%+4.0%Source
FY2019~$18.5B~$5.9B31.9%—Source
Full Novo Nordisk financials

Where the revenue comes from

Eli Lilly

  • Branded Prescription MedicinesPrimary

    Sales of patent-protected medicines through wholesalers, pharmacies, health systems, and international channels.

  • Collaborations and Licensing

    Supporting

    Milestones, royalties, and collaboration economics connected to research, development, and commercialization partnerships.

Novo Nordisk

  • GLP-1 Diabetes MedicinesMajor

    Ozempic, Rybelsus, and related diabetes products sold globally.

  • Obesity Care

    Major growth

    Wegovy and related obesity-care products sold through prescription channels.

  • Insulin And Diabetes CareMaterial

    Insulin and other diabetes medicines across developed and emerging markets.

  • Rare Disease

    Complementary

    Hemophilia, growth hormone, and rare endocrine therapies.

  • Pipeline And Lifecycle ExpansionFuture

    New indications, formulations, and next-generation metabolic medicines.

Business model and strategy

Eli Lilly

How it makes money

Eli Lilly and Company is an innovation-driven global pharmaceutical titan that discovers, develops, manufactures, and commercializes human therapeutics across endocrinology, oncology, immunology, and neuroscience.

Growth strategy

Lilly's growth strategy has three parts: expand incretin supply and indications, add oral and next-generation obesity medicines, and diversify through oncology, immunology, neuroscience and genetic medicine. Foundayo (orforglipron) was approved by the FDA on April 1, 2026 and launched through LillyDirect, telehealth and U.S. retail pharmacies. Retatrutide, a GIP/GLP-1/glucagon triple agonist, is in Phase 3.

Competitive advantage

Eli Lilly's formidable economic moat is founded on its multi-decade dominance in peptide synthesis, patent-protected intellectual property, and extensive global sterile manufacturing infrastructure.

Eli Lilly business model in full

Novo Nordisk

How it makes money

Novo Nordisk A/S is a world-leading Danish healthcare company that develops, manufactures, and markets biological medicines focused primarily on diabetes care and obesity management, supplemented by rare disease therapies.

Growth strategy

Under CEO Mike Doustdar the strategy is to cut costs (about 9,000 roles targeted in 2025, with reported headcount down further since), push volume through cheaper self-pay and oral options such as the Wegovy pill, roll out Wegovy 7.2 mg internationally, and rebuild the pipeline through deals such as the Akero Therapeutics acquisition for MASH and in-licensing agreements.

Competitive advantage

Novo Nordisk commands an unmatched century-long moat in protein engineering, industrial-scale yeast fermentation, and specialized pen-injector drug delivery systems. Controlling approximately one-third of the global diabetes treatment market, Novo Nordisk possesses unrivaled clinical relationships with endocrinologists, primary care physicians, and healthcare payers worldwide.

Novo Nordisk business model in full

Questions about Eli Lilly vs Novo Nordisk

Which company has higher revenue — Eli Lilly and Company or Novo Nordisk A/S?

Eli Lilly and Company had $65.2B (FY2025), while Novo Nordisk A/S had ~$47B (FY2025). By latest annual revenue, Eli Lilly and Company is the larger business, with Novo Nordisk A/S showing a smaller revenue base.

What is the market cap of Eli Lilly and Company vs Novo Nordisk A/S?

Eli Lilly and Company's market capitalisation stands at $1.06T, while Novo Nordisk A/S's is $170.0B. Eli Lilly and Company carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Novo Nordisk A/S.

How does revenue per employee compare for Eli Lilly and Company and Novo Nordisk A/S?

Eli Lilly and Company has $1.30M / employee in revenue per employee, while Novo Nordisk A/S has $704k / employee. Headcounts may use different dates, so the ratio alone does not establish which business operates more efficiently.

How do Eli Lilly and Company and Novo Nordisk A/S make money?

Eli Lilly and Company and Novo Nordisk A/S generate revenue in fundamentally different ways. Eli Lilly and Company: Eli Lilly and Company is an innovation-driven global pharmaceutical titan that discovers, develops, manufactures, and commercializes human therapeutics across endocrinology, oncology, immunology, and neuroscience. Novo Nordisk A/S: Novo Nordisk A/S is a world-leading Danish healthcare company that develops, manufactures, and markets biological medicines focused primarily on diabetes care and obesity management, supplemented by rare disease therapies.

Which company is valued higher relative to revenue — Eli Lilly and Company or Novo Nordisk A/S?

On a price-to-sales (P/S) basis, Eli Lilly and Company trades at 16.3x P/S and Novo Nordisk A/S at 3.6x P/S. Eli Lilly and Company commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Novo Nordisk A/S. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.

Is Eli Lilly and Company bigger than Novo Nordisk A/S?

By last reported revenue, Eli Lilly and Company ($65.2B (FY2025)) is the larger company compared to Novo Nordisk A/S (~$47B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Eli Lilly vs Novo Nordisk overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.